Company: STAA
Filing Date: 2025-10-24
Form Type: DFAN14A
Source: 0001213900-25-102242
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-24
Form: DFAN14A
Chunk 2
---
IPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREENProxy Card will be furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on October 22, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

Appalled that STAAR’s Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner

Urges STAAR to Give Up on Misbegotten Transaction and Refocus on Running the Business

Intends to Seek Removal of STAAR Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher from the Board at a Special Meeting</div>

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates
(“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR”
or the “Company”) (NASDAQ: STAA), today issued the following statement regarding the agreement between STAAR and Alcon Inc.
(“Alcon”) (NYSE: ALC) to postpone a shareholder vote on the proposed sale of the Company.

Neal C. Bradsher, Broadwood Founder and President, said:

“The decision to postpone a shareholder vote on the
sale of STAAR to Alcon is the latest in a long string of bad decisions by this Board, which ran a deeply flawed sale process at the wrong
time and agreed to an inadequate price. For these reasons, all three major proxy advisory firms oppose the proposed transaction.

A little more than two weeks ago, the Board said: ‘[T]he ultimate decision rests in the hands of all STAAR stockholders, which is exactly where it should be.’ But now, faced with
overwhelming and public shareholder opposition to the deal, the Board, with full visibility into the vote tally, has stripped shareholders
of their right to a timely final vote.

Shareholders can reasonably assume that no such postponement
would have occurred if the vote tally had